Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus*
Lido
6163
Vezesque se leu este artigo
2776
Total PDF
3387
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 61 | 28 | 89 |
| 2025 5 | 152 | 71 | 223 |
| 2025 4 | 114 | 50 | 164 |
| 2025 3 | 122 | 43 | 165 |
| 2025 2 | 143 | 87 | 230 |
| 2025 1 | 94 | 60 | 154 |
| 2024 12 | 77 | 75 | 152 |
| 2024 11 | 113 | 61 | 174 |
| 2024 10 | 88 | 90 | 178 |
| 2024 9 | 148 | 106 | 254 |
| 2024 8 | 127 | 121 | 248 |
| 2024 7 | 114 | 117 | 231 |
| 2024 6 | 101 | 69 | 170 |
| 2024 5 | 86 | 75 | 161 |
| 2024 4 | 87 | 81 | 168 |
| 2024 3 | 82 | 76 | 158 |
| 2024 2 | 82 | 73 | 155 |
| 2024 1 | 73 | 42 | 115 |
| 2023 12 | 49 | 53 | 102 |
| 2023 11 | 52 | 66 | 118 |
| 2023 10 | 50 | 58 | 108 |
| 2023 9 | 45 | 48 | 93 |
| 2023 8 | 41 | 32 | 73 |
| 2023 7 | 48 | 21 | 69 |
| 2023 6 | 44 | 45 | 89 |
| 2023 5 | 45 | 17 | 62 |
| 2023 4 | 42 | 23 | 65 |
| 2023 3 | 46 | 33 | 79 |
| 2023 2 | 46 | 42 | 88 |
| 2023 1 | 61 | 38 | 99 |
| 2022 12 | 71 | 22 | 93 |
| 2022 11 | 53 | 37 | 90 |
| 2022 10 | 60 | 36 | 96 |
| 2022 9 | 38 | 50 | 88 |
| 2022 8 | 22 | 42 | 64 |
| 2022 7 | 42 | 46 | 88 |
| 2022 6 | 41 | 54 | 95 |
| 2022 5 | 31 | 34 | 65 |
| 2022 4 | 36 | 44 | 80 |
| 2022 3 | 47 | 55 | 102 |
| 2022 2 | 39 | 37 | 76 |
| 2021 1 | 53 | 56 | 109 |
| 2021 12 | 50 | 45 | 95 |
| 2021 11 | 38 | 40 | 78 |
| 2021 10 | 40 | 57 | 97 |
| 2021 9 | 16 | 22 | 38 |
| 2021 8 | 19 | 20 | 39 |
| 2021 7 | 19 | 21 | 40 |
| 2021 6 | 14 | 31 | 45 |
| 2021 5 | 25 | 31 | 56 |
| 2021 4 | 150 | 173 | 323 |
| 2021 3 | 9 | 9 | 18 |
| 2021 2 | 13 | 6 | 19 |
| 2020 1 | 20 | 4 | 24 |
| 2020 12 | 8 | 3 | 11 |
Mostrar tudo
